Stanford Scientists Develop Universal Nasal Vaccine Shielding Against COVID Flu Pneumonia and Major Allergens

Stanford Medicine researchers unveil a universal nasal vaccine protecting against COVID, flu, and allergies by activating long-lasting lung immune defenses.

By: AXL Media

Published: Feb 23, 2026, 10:14 AM EST

Source: The information in this article was sourced from ScienceDaily - https://www.sciencedaily.com/releases/2026/02/260222092258.htm

Breaking the Specificity Paradigm in Modern Vaccinology

Traditional vaccines rely on antigen specificity, targeting specific surface structures of pathogens to build immunity. However, rapid viral mutations often render these shots less effective over time, requiring constant updates and boosters. According to senior author Bali Pulendran, PhD, this traditional approach has been the dominant model for over 230 years. The new Stanford research aims to move beyond this limitation by creating a synthetic vaccine that mimics immune communication signals rather than copying a specific viral part. This shift represents a fundamental change in how scientists approach infectious disease prevention, focusing on broad alertness rather than narrow recognition.

Coordinating the Innate and Adaptive Immune Frontiers

The experimental formula, currently designated as GLA-3M-052-LS+OVA, works by bridging the innate and adaptive immune systems. While the innate system usually responds quickly but fades within days, this new approach maintains a heightened state of defense for several months. According to report findings, the vaccine recruits T cells to the lungs which then send signals to keep innate immune cells switched on. Lead author Haibo Zhang, PhD, observed that this coordinated response allows the body to launch a virus-specific attack in as little as three days, significantly faster than the two weeks typically required in unvaccinated subjects.

Proving Broad Efficacy Against Diverse Biological Threats

In rigorous mouse trials, the nasal spray demonstrated efficacy against a wide array of respiratory dangers. Vaccinated subjects showed high levels of protection against SARS-CoV-2 and other coronaviruses, alongside common hospital infections like Staphylococcus aureus. According to the research team, the vaccine reduced viral levels in the lungs by 700-fold compared to control groups. Beyond pathogens, the study also found that the treatment successfully blocked allergic reactions to house dust mites. This suggests a multi-functional capability that could eventually simplify public health interventions by combining several preventative measures into a single delivery system.